Literature DB >> 6228279

Hypoxia-induced cardiac hypertrophy in rabbits treated with verapamil and nifedipine.

I D Dukes, E M Vaughan Williams.   

Abstract

Young rabbits were exposed, eight at a time, to 310 h of hypoxia (O2 at 70-80 torr), at atmospheric pressure. The animals were injected with 1 mg kg-1 nifedipine (F) or 5 mg kg-1 verapamil (V) or an equivalent volume of the vehicle (H) (Cremophor EL), i.p. twice a day. A fourth group (N), also injected with vehicle, was not made hypoxic. The animals were from 6 litters, 6 rabbits in each litter, and were distributed so that every group had litter mates in the other groups. Right ventricular hypertrophy was induced in all the hypoxic groups (H, +39%; V, +46%; F, +44%). Differences between groups were not statistically significant, but all were significantly hypertrophied relative to their normoxic litter mates (N). The right atria were less hypertrophied (H, +3.6%; V, +20%; F, +21.6%), but there was no left ventricular or left atrial hypertrophy. There was also a small increase in haematocrit in the hypoxic groups (H, +20.6%; V, +17.5%; F, +28.8%). The doses administered were equivalent to the highest used clinically producing blood levels of verapamil and nifedipine within or above the clinical range and had no effect on the development of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6228279      PMCID: PMC2045028          DOI: 10.1111/j.1476-5381.1983.tb10026.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  11 in total

1.  The effects of prolonged beta-adrenoceptor blockade on heart weight and cardiac intracellular potentials in rabbits.

Authors:  E M Williams; A E Raine; A A Cabrera; J M Whyte
Journal:  Cardiovasc Res       Date:  1975-09       Impact factor: 10.787

2.  Left ventricular hypertrophy in coronary artery disease. A cardiomyopathy syndrome following myocardial infarction.

Authors:  K L Gould; K Lipscomb; G W Hamilton; J W Kennedy
Journal:  Am J Med       Date:  1973-11       Impact factor: 4.965

3.  Hypertrophic obstructive cardiomyopathy in an infant--propranolol therapy for three years.

Authors:  D G Shand; C G Sell; J A Oates
Journal:  N Engl J Med       Date:  1971-10-07       Impact factor: 91.245

Review 4.  The frontiers of cardiomyopathy.

Authors:  J F Goodwin
Journal:  Br Heart J       Date:  1982-07

Review 5.  Cardiac sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy.

Authors:  I Ostman-Smith
Journal:  Clin Sci (Lond)       Date:  1981-09       Impact factor: 6.124

6.  The influence of indomethacin on renal concentrating and diluting capacity in sickle cell nephropathy.

Authors:  P E De Jong; L T De Jong-van den Berg; D De Zeeuw; A J Donker; H Schouten; L W Statius van Eps
Journal:  Clin Sci (Lond)       Date:  1982-07       Impact factor: 6.124

7.  Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum.

Authors:  S C Cole; R J Flanagan; A Johnston; D W Holt
Journal:  J Chromatogr       Date:  1981-11-20

8.  Pulmonary vascular effects of verapamil.

Authors:  A Davidson; I McMurtry; J T Reeves
Journal:  Am Heart J       Date:  1978-06       Impact factor: 4.749

Review 9.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

10.  Hypoxic cardiac hypertrophy is not inhibited by cardioselective or non-selective beta-adrenoceptor antagonists.

Authors:  P Dennis; E M Vaughan Williams
Journal:  J Physiol       Date:  1982-03       Impact factor: 5.182

View more
  1 in total

1.  Mild hypoxia-induced cardiomyocyte hypertrophy via up-regulation of HIF-1α-mediated TRPC signalling.

Authors:  Wenfeng Chu; Lin Wan; Dan Zhao; Xuefeng Qu; Fulai Cai; Rong Huo; Ning Wang; Jiuxin Zhu; Chun Zhang; Fangfang Zheng; Ruijun Cai; Deli Dong; Yanjie Lu; Baofeng Yang
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.